IP Library › Granted Patent US 11,555,068
Granted Patent B2
US 11,555,068 · App. 16/583,730 · Granted Jan 17, 2023

Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Inventor: Mir Imran (Los Altos Hills, CA)
Assignee: Rani Therapeutics, LLC
C07K16/241A61K9/0053A61K9/4808A61K31/155A61M5/00A61M25/10A61M31/002A61K2039/54A61K2039/542C07K2317/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,555,068
App. No.
16/583,730
Granted
Jan 17, 2023
Kind
B2
Abstract

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Claims (21)

1. A method for delivering infliximab to a patient, said method comprising:

providing a swallowable enclosure having an interior, a delivery means, and containing an infliximab preparation in a solid form coupled to the delivery means, the infliximab preparation comprising a therapeutically effective dose of infliximab, the delivery means having a first configuration and a second configuration, the preparation being contained within the interior in the first configuration and advanced out of the interior and into a gastro-intestinal (GI) lumen wall in the second configuration so as to deliver the infliximab preparation into the GI lumen wall, the enclosure protecting the infliximab preparation from degradation by GI fluids, the infliximab preparation supplied in the enclosure in a solid form which is delivered from the enclosure into the GI lumen wall by application of force on the preparation; and

triggering the delivery means within the GI lumen responsive to a condition in the lumen to advance the infliximab preparation in a solid form out of the interior of the enclosure and deliver the infliximab preparation in a solid form into the GI lumen wall by application of force on the preparation, wherein the dose of infliximab is released into the patient's blood stream.

2. The method of claim 1 , wherein the GI lumen is the small intestine.

3. The method of claim 1 , wherein the GI lumen is the stomach.

4. The method of claim 1 , wherein the condition is a selected pH.

5. The method of claim 4 , wherein the pH is above about 7.1.

6. The method of claim 1 , wherein the dose of infliximab in the infliximab preparation is in a range from about 1 to 10 mg.

7. The method of claim 1 , wherein the dose of infliximab in the infliximab preparation is about 5 mg.

8. The method of claim 1 , wherein the infliximab preparation comprises at least one pharmaceutical excipient.

9. The method of claim 1 , wherein the infliximab preparation comprises at least one pharmaceutical excipient.

10. The method of claim 9 , wherein the at least one pharmaceutical excipient comprises at least one of a binder, a preservative or a disintegrant.

11. The method of claim 1 , further comprising retaining the infliximab preparation within the GI lumen wall.

12. The method of claim 11 , wherein retaining comprises anchoring a portion of the infliximab preparation in GI lumen wall tissue.

13. The method of claim 1 , wherein the infliximab preparation is advanced completely into the GI lumen wall by such application of force.

14. The method of claim 1 , wherein the infliximab preparation is advanced through the GI lumen wall by such application of force.

15. The method of claim 1 , wherein the force is a mechanical force applied to a surface of the infliximab preparation.

16. The method of claim 1 , wherein the release of the infliximab dose into the patient's blood stream results in a t % of about 40 days.

17. The method of claim 1 , wherein the delivery means comprises an expandable balloon.

18. The method of claim 1 , wherein the delivery means comprises a spring.

19. The method of claim 1 , wherein the infliximab preparation is shaped as a tissue penetrating member.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Dec 19, 2025
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
To: RANI THERAPEUTICS, LLC
Reel/Frame 073971/0117 →
SECURITY INTEREST Recorded Aug 9, 2022
From: RANI THERAPEUTICS, LLC
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P., AS AGENT
Reel/Frame 061131/0478 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2019
From: IMRAN, MIR
To: RANI THERAPEUTICS, LLC
Reel/Frame 050502/0066 →
Continuity (8)
Continuation 15192915 · Jun 24, 2016
Continuation 13539019 · Jun 29, 2012
Continuation In Part 12978301 · Dec 23, 2010
Continuation In Part 12978233 · Dec 23, 2010
Continuation In Part 12978164 · Dec 23, 2010
Provisional Application 61571648 · Jun 30, 2011
Provisional Application 61571641 · Jun 29, 2011
Related Publication 20200095312A1 · Mar 26, 2020
Cited By (2)
US 12,263,325 US 12,268,831